Please assess the completion status of the following clinical trial:

Trial Title: Bela 8 Week Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age ≥18 years currently),~* First-time renal transplant recipients of either living donor or deceased donor,~  1. who were initiated on belatacept at the time of transplant and~ 2. are at least one year post-transplant and off CNI therapy for at least 6 months.~* Patients at low immunologic risk, defined as~  1. patients with a first transplant who have a PRA \< 50 against class I and class II antigens,~ 2. no DSA (donor-specific antibodies),~ 3. who have not had more than one episode of rejection, and~ 4. no episodes of rejection within the last 6 months prior to enrollment, and~ 5. no rejection with a grade of IIB or above.~Exclusion Criteria:~* Not first renal transplant, or multi-organ transplant recipient~* History of greater than one episode of biopsy-proven acute rejection, or of rejection of Banff 97 grade IIB or greater, or rejection within the last 6 months.~* Pregnancy (women of childbearing potential must use adequate contraception during study)~* Unwilling to receive all belatacept infusions at the Emory Transplant Center~* Calculated Glomerular Filtration Rate (GFR) less than 35.~* Serum creatinine at enrollment over 30% higher than 3 months (±4 weeks) prior to randomization~* HbA1C greater than 8 at enrollment~* Recent history of significant proteinuria (protein/Cr ratio \>1)~* Non-standard belatacept dosing (e.g. dose other than 5 mg belatacept/kg body weight)~* Cellcept dose less than 500 mg po bid.~* Prednisone dose greater than 5mg po qd within 3 months of randomization~* Patients not currently taking prednisone~* Active infection, or antibiotic or antiviral drug therapy within 1 month of randomization~* Evidence of Cytomegalovirus (CMV) viremia or clinical CMV infection within last 3 months.~* Polyomavirus BK PCR (polymerase chain reaction) load greater then 4.3 (copy number greater than 20,0000) within 3 months of randomization~* Known hepatitis B surface antigen-positive or PCR-positive for hepatitis B (testing not required)~* Known HIV (human immunodeficiency virus infection) (testing not required)~* Presence of donor specific antibody by Luminex single antigen assessment, or panel reactivity (PRA) above 50%.~* History of substance abuse or psychiatric disorder not compatible with study adherence and follow up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belatacept 8-weekly (Type: EXPERIMENTAL): Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
- Belatacept 4-weekly (Type: ACTIVE_COMPARATOR): Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).